Literature DB >> 24337617

[Chronic migraine].

H C Diener1, D Holle, D Müller, S Nägel, K Rabe.   

Abstract

The classification of the International Headache Society (IHS) generally differentiates episodic from chronic headache. Chronic migraine is defined as headache on 15 and more days a month over more than 3 months and headache on 8 days or more fulfils the criteria for migraine or were triptan/ergot-responsive when thought to be migrainous in early stages of the attack. The prevalence of chronic migraine is estimated at 2-4 %. The quality of life is highly compromised in this condition and comorbidities are much more frequent compared to episodic migraine. Data from prospective randomized studies are scarce as most patients with chronic migraine were excluded from previous trials and only few studies were conducted for this condition. The efficacy for prophylactic treatment compared with placebo is proven for topiramate and onabotulinum toxin A.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337617     DOI: 10.1007/s00115-012-3625-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  37 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  Time trends in the prevalence of headache disorders. The Nord-Trondelag Health Studies (HUNT 2 and HUNT 3).

Authors:  Mattias Linde; Lars Jacob Stovner; John-Anker Zwart; Knut Hagen
Journal:  Cephalalgia       Date:  2010-12-01       Impact factor: 6.292

3.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

4.  Triptan-induced latent sensitization: a possible basis for medication overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Josephine Lai; Juliana Chichorro; Ian Meng; David W Dodick; Todd W Vanderah; Gregory Dussor; Frank Porreca
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

5.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

6.  Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Authors:  Joel R Saper; Alvin E Lake; Deborah T Cantrell; Paul K Winner; Jeffery R White
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

7.  Cerebrovascular response to repetitive visual stimulation in interictal migraine with aura.

Authors:  K Nedeltchev; M Arnold; M Schwerzmann; A Nirkko; F Lagger; H P Mattle; M Sturzenegger
Journal:  Cephalalgia       Date:  2004-09       Impact factor: 6.292

Review 8.  Measuring the impact of headache in children: a critical review of the literature.

Authors:  D Kernick; J Campbell
Journal:  Cephalalgia       Date:  2008-09-16       Impact factor: 6.292

9.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

10.  A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Authors:  Ninan T Mathew; Sayyed Farhan A Jaffri
Journal:  Headache       Date:  2009 Nov-Dec       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.